semaglutide and liver damage Focus on 2.4 mg/week for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis - Petta - 2025 - International Semaglutide (Ozempic/Wegovy) dramatically improves fatty

No toxic metabolites

As per the International Federation of Pharmaceutical Manufacturers & Associations, 59 new drugs were introduced in 2018, and more than 8,000 compounds are currently being developed globally

The SUSTAIN-6 trial evaluated semaglutide in patients with type 2 diabetes at high cardiovascular risk and found a 26% reduction in major adverse cardiovascular events (MACE)a composite endpoint including cardiovascular death, non-fatal heart attack, and non-fatal strokecompared to placebo (HR 0.74

Irregular or inconsistent dosing weakens outcomes, especially when sleep timing and recovery are disrupted